Characterization of cancer-linked BRCA1-BRCT missense variants and their interaction with phosphoprotein targets

Proteins: Structure, Function and Bioinformatics

Volumn 77, Issue 2, 2009, Pages 464-476

  Drikos, Ioannis ^a   Nounesis, George ^b   Vorgias, Constantinos E ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Biomolecular Physics Laboratory   (Iceland)

Author keywords

BRCA1 BRCT; Breast cancer; CD; DSC; ITC; Mutations; pBACH1 BRIP1; pCtIP

Indexed keywords

BRCA1 PROTEIN;

ARTICLE; CIRCULAR DICHROISM; DIFFERENTIAL SCANNING CALORIMETRY; GEL FILTRATION CHROMATOGRAPHY; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY; TANDEM REPEAT;

BRCA1 PROTEIN; BREAST NEOPLASMS; CLONING, MOLECULAR; FEMALE; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; PHOSPHOPROTEINS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; THERMODYNAMICS;

PROKARYOTA;

EID: 70349469609     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22460     Document Type: Article

References (40)

1. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;224:120-122. (Pubitemid 24345332)
2. Ferla R, Calo V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci G, Bazan V, Russo A. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007;6:93-98.
3. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Nat Cancer Inst 2002;9418:1365-1372. (Pubitemid 35154141)
4. Robles-Diaz L, Goldfrank DJ, Kauff ND, Robson M, Offit K. Hereditary ovarian cancer in Askenazi Jews. Fam Cancer 2004;3:259-264. (Pubitemid 39491743)
5. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130. (Pubitemid 36530000)
6. Williams RS, Green R, Glover JN. Crystal structure of the BRCT repeat region from the breast cancer associated protein BRCA1. Nat Struct Biol 2001;10:838-842. (Pubitemid 32923600)
7. Joo WS, Jeffrey PD, Cantor SB, Finnin MS, Livingston DM, Pavlretich NP. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the BRCA1 BRCT structure. Genes Dev 2002;16:583-593. (Pubitemid 34212491)
8. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, Abeisighe S, Krawczak M, Cooper DN. Human gene mutation database (HGMD). Hum Mutat 2003;21:577-581.
9. Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, Frank TS. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet 1995;9:439-443.
10. Rodriguea JA, Au WW, Henderson BR. Cytoplasmic mislocalization of BRCA1 caused by cancer associated mutations in the BRCT domain. Exp Cell Res 2004;293:14-21.
11. Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, Schnitt S, Livingston DM. Location of BRCA1 in human breast and ovarian cancer cells. Science 1996;272:123-126.
12. Wilson CA, Ramos L, Vilasenor M, Andres KH, Press MH, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RZ, Kanter MH, Cohen S, Calzone F, Slamon D. Localization of human BRCA1 and its loss in high grade non inherited breast carcinomas. Nature 1999;21:236-241. (Pubitemid 29070375)
13. Mirkovic N, Marti-Remon MA, Weber BL, Sali A, Monteiro NA. Structure based assessment of missense mutations in human BRCA1: Implications for breast and ovarian cancer predisposition. Cancer Res 2004;64:3790-3797. (Pubitemid 38701757)
14. Ray H, Moreau K, Dizin E, Callebaut I. ACCA phosphopeptide recognition by the BRCT repeats of BRCA1. J Mol Biol 2006;359:973-982. (Pubitemid 43831925)
15. Derbyshire DJ, Basu BP, Serpell LC, Joo WS, Date T, Iwabuchi K, Doherty AJ. Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J 2002;21:3863-3872. (Pubitemid 34787058)
16. Botuyan MV, Nomine Y, Yu X, Juranic N, Macura S, Chen J, Mer G. Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. Structure 2004;24:1137-1146. (Pubitemid 38900756)
17. Varma AK, Brown RS, Birrane G, Ladias JA. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex. Biochemistry 2005;44:10941-10946. (Pubitemid 41209030)
18. Kumaraswamy E, Shiekhattar R. Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase. Mol Cell Biol 2007;19:6733-6741. (Pubitemid 47483625)
19. Clapperton JA, Manke IA, Lowery DM, Ho T, Haire LF, Yaffe MB, Smerdon MB. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol 2004;11:512-518. (Pubitemid 38691917)
20. Chinnadurai G. CtIP, a candidate tumor susceptibility gene is a team player with luminaries. Biochim Biophys Acta 2006;1765:67-73. (Pubitemid 41752941)
21. Hammet A, Magill C, Heierhorst J, Jackson SP. Rad9 BRCT domain interaction with phosphorylated H2AX regulates the G1 checkpoint in budding yeast. EMBO Rep 2007;8:851-857. (Pubitemid 350001429)
22. Shiozaki EN, Gu L, Yan N, Shi Y. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. Mol Cell 2004;14:405-412. (Pubitemid 38591411)
23. Williams RS, Lee MS, Hau DD, Glover JN. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat Struct Mol Biol 2004;14:519-525. (Pubitemid 38691918)
24. Yu X, Chen J. DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol 2004;24:9478-9486. (Pubitemid 39391684)
25. Nikolopoulos G, Pyrpassopoulos S, Thanassoulas A, Klimentzou P, Zikos C, Vlassi M, Vorgias CE, Yannoukakos D, Nounesis G. Thermal unfolding of BRCA1-BRCT variants. Biochim Biophys Acta 2007;6:772-780.
26. Williams RS, Glover JN. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. J Biol Chem 2003;278:2630-2635.
27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
28. Robinson DW, Bradford GE. Cellular response to selection for rapid growth in mice. Growth 1969;33:221.
29. Stanley G, Hippel PH. Calculation of protein extinction coefficients from amino acids sequence data. Anal Biochem 1989;2:319-326.
30. Pace N, Valdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci 1995;4:2411-2423.
31. Pyrpassopoulos S, Ladopoulou A, Vlassi M, Papanikolau Y, Vorgias CE, Yannoukakos D, Nounesis G. Thermal denaturation of the BRCT tandem repeat region of human tumour suppressor gene product BRCA1. Biophys Chem 2005;114:1-12. (Pubitemid 40403524)
32. Deffenbaugh AM, Frank TS, Hoffman M, Cannon-Albright L, Neuhausen SL. Characterization of common BRCA1 and BRCA2 variants. Genet Test 2002;6:119-121. (Pubitemid 34894240)
33. Humphrey JS, Salim A, Erdos M, Collins FS, Brody LC, Klausner RD. Human BRCA1 inhibits growth in yeast: potential use in diagnostic testing. Proc Natl Acad Sci USA 1997;11:5820-5825. (Pubitemid 27241855)
34. Williams RS, Chasman DI, Hau DD, Hui B, Lan AY, Glover JN. Detection of protein folding detects caused by BRCA1-BRCT truncation and missense mutations. J Biol Chem 2003;278:53007-53016. (Pubitemid 38035903)
35. Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, Beers EH, Joosse SA, Wong N, Novak D, Quenneville LA, Grist SA, Nederlof PM, David E Goldgar DE, Tavtigian SV, Monteiro AN, Ladias JA, Foulkes W. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phopshpeptide binding pocket: a multi modal approach. Eur J Hum Genet 2008;7:820-832. (Pubitemid 351865680)
36. Mark Glover JN. Insights of the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain. Fam Cancer 2006;5:89-93.
37. Loladze VV, Ermolenko DN, Makhatadze GI. Thermodynamic consequences of burial of polar and non-polar amino acid residues in the protein interior. J Mol Biol 2002;320:343-357.
38. Kaufman B, Laitman Y, Carvalho MA, Endelman L, Menachem TD, Zidan J, Monteiro AN, Friedman E. The P1812A and P25T BRCA1 and the 5164del4 BRCA2 mutations. Occurrence in high-risk non Askenazi Jews. Genet Test 2006;10:200-207.
39. Martinez-Ferrandis JI, Vega A, Chirivella I, Marin-Garcia P, Insa A, Lluch A, Carracedo A, Chaves FJ, Garcia-Condle J, Cervantes A, Armengod ME. Mutational analysis of BRCA1 and BRCA2 in Mediterranean Spanish women with early onset breast cancer: identification of three novel pathogenic mutations. Hum Mutat 2003;659:1-5.
40. Nomine Y, Botuyan V, Bajzer Z, Owen WG, Caride AJ, Wasielewski E, Mer G. Kinetic analysis of interaction of BRCA1 tandem breast cancer C-terminal domains with phosphorylated peptides reveals two binding conformations. Biochemistry 2008;47:9866-9879.